Cell Therapeutics, Inc. Announces Exercise of Underwriters' Common Stock Over-Allotment Option
Tuesday August 31, 10:31 am ET
SEATTLE, Aug. 31 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced the underwriters of its recent 9,000,000 share common stock public offering exercised their over-allotment option and purchased 1,350,000 additional shares of common stock from CTI at a price of $4.75 per share minus the underwriting discounts. CTI sold a total of 10,350,000 shares of common stock in the offering, including the shares covered by the exercised over-allotment option, for aggregate gross proceeds of approximately $49.16 million.
UBS Securities LLC and CIBC World Markets acted as joint book-running managers in the offering. WR Hambrecht + Co, LLC, Delafield Hambrecht, Inc. and Punk, Ziegel & Company, L.P. acted as co-managers. |
